















- tion: a prospective evaluation of new dosing regimens. *J Clin Oncol* 1991;9:1215-23.
20. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. *BMC Pharmacol Toxicol* 2014;15:47.
  21. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. *J Cancer Res Clin Oncol* 2008;134:75-82.
  22. Frickhofen N, Beck FJ, Jung B, et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. *Ann Oncol* 2002;13:797-801.
  23. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. *N Engl J Med* 2005;353:172-87.
  24. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. *Circulation* 2011;124:1687-91.
  25. Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. *JACC Heart Fail* 2013;1:72-8.
  26. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. *J Clin Oncol* 2015;33:4210-18.
  27. Li W, Croce K, Steensma DP, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. *J Am Coll Cardiol* 2015;66:1160-78.
  28. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med* 2014;371:213-23.
  29. Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. *Clin Lymphoma Myeloma Leuk* 2017;17:31-7e13.
  30. Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. *Blood* 2017 [Epub ahead of print].
  31. Jain V, Bahia J, Mohebtash M, Barac A. Cardiovascular complications associated with novel cancer immunotherapies. *Curr Treat Options Cardiovasc Med* 2017;19:36.
  32. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. *N Engl J Med* 2016;375:1749-55.
  33. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med* 2013;368:987-98.
  34. Bijl JM, Roos MM, van Leeuwen-Segarceanu EM, et al. Assessment of valvular disorders in survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy +/- chemotherapy. *Am J Cardiol* 2016;117:691-6.
  35. Huang TL, Hsu HC, Chen HC, et al. Long-term effects on carotid intima-media thickness after radiotherapy in patients with nasopharyngeal carcinoma. *Radiat Oncol* 2013;8:261.
  36. Halak M, Fajer S, Ben-Meir H, et al. Neck irradiation: a risk factor for occlusive carotid artery disease. *Eur J Vasc Endovasc Surg* 2002;23:299-302.
  37. Huang CC, Huang TL, Hsu HC, et al. Long-term effects of neck irradiation on cardiovascular autonomic function: a study in nasopharyngeal carcinoma patients after radiotherapy. *Muscle Nerve* 2013;47:344-50.
  38. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. *CA Cancer J Clin* 2014;64:252-71.
  39. Chow EJ, Mueller BA, Baker KS, et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. *Ann Intern Med* 2011;155:21-32.
  40. Mulrooney DA, Armstrong GT, Huang S, et al. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: a cross-sectional study. *Ann Intern Med* 2016;164:93-101.
  41. Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. *N Engl J Med* 2016 [Epub ahead of print].
  42. Barac A, Murtagh G, Carver JR, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. *J Am Coll Cardiol* 2015;65:2739-46.
  43. Barros-Gomes S, Herrmann J, Mulvagh SL, et al. Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic. *Cardio-Oncology* 2016;2(5).
  44. Snipelisky D, Park JY, Lerman A, et al. How to develop a cardio-oncology clinic. *Heart Fail Clin* 2017;13:347-59.
  45. Montazeri K, Unitt C, Foody JM, et al. ABCDE steps to prevent heart disease in breast cancer survivors. *Circulation* 2014;130:e157-9.
  46. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline. *J Clin Oncol* 2017;35:893-911.
  47. Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. *J Am Coll Cardiol* 2014;63:809-16.
  48. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. *J Am Coll Cardiol* 2000;36:517-22.
  49. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2014;27:911-39.
  50. De Smet K, Verdries D, Tanaka K, et al. MRI in the assessment of non ischemic myocardial diseases. *Eur J Radiol* 2012;81:1546-8.
  51. Moslehi JJ, Johnson DB, Sosman JA. Myocarditis with immune checkpoint blockade. *N Engl J Med* 2017;376:292.
  52. Sillman C, Morin J, Thomet C, et al. Adult congenital heart disease nurse coordination: Essential skills and role in optimizing team-based care a position statement from the International Society for Adult Congenital Heart Disease (ISACHD). *Int J Cardiol* 2017;229:125-31.
  53. Johnson SA, Giesie PD, Ireland AM, et al. On the scene: developing a nurse care coordinator role at city of hope. *Nurs Adm Q* 2016;40:39-50.
  54. Lenihan DJ, Hartlage G, DeCara J, et al. Cardio-oncology training: a proposal from the International Cardioncology Society and Canadian Cardiac Oncology Network for a new multidisciplinary specialty. *J Card Fail* 2016;22:465-71.
  55. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. *Circulation* 2004;109:2749-54.
  56. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. *J Clin Oncol* 2010;28:3910-6.
  57. Skovgaard D, Hasbak P, Kjaer A. BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equi-



- librium radionuclide ventriculography. PLoS One 2014;9:e96736.
58. Zardavas D, Suter TM, Van Veldhuisen DJ, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol 2017;35:878-84.
59. Brinda BJ, Viganego F, Vo T, et al. Anti-VEGF-induced hypertension: a review of pathophysiology and treatment options. Curr Treat Options Cardiovasc Med 2016;18:33.

Non commercial use only